Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer
Conditions
Interventions
Olaparib
Platinum-based Chemotherapy
Locations
9
Canada
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre hospitalier de l'Université de Montréal (CHUM
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Auckland City Hospital
Grafton, Auckland, New Zealand
Start Date
July 19, 2016
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
January 17, 2024
NCT06257264
NCT06964009
NCT06547840
NCT05080946
NCT06503146
NCT07498829
Lead Sponsor
University Health Network, Toronto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions